Introduction
Phosphodiesterase-5 (PDE-5) inhibitors play an important role in the treatment of complications of cirrhosis. They have been used successfully to treat portopulmonary hypertension (PPHTN) [1] [2] [3] [4] , a complication in 5 % of subjects with cirrhosis [5] . Additionally, previous studies showed that PDE-5 inhibitors reduced portal pressures and hepatic venous pressure gradients, thereby improving hemodynamics in cirrhosis [6] [7] [8] . Moreover, in cirrhotic rats, PDE-5 inhibitors increased fractional excretion of Na, reduced plasma renin levels, and improved renal blood flow and glomerular filtration rate [9] .
In cirrhosis, diminished intrahepatic nitric oxide (NO) levels [6] are associated with elevated asymmetric dimethylarginine levels that inhibit NO synthesis by competing with L-arginine for NO synthase [10, 11] . In turn, reduced intrahepatic NO levels result in dysfunction of NO-activated guanylate cyclase and, consequently, reduced sinusoidal cyclic guanosine 3 0 , 5 0 monophosphate (cGMP) [8] . cGMP depletion increases intrahepatic sinusoidal pressure [8] , splanchnic vasodilation, activation of the renin-angiotensin-aldosterone system, and development of renal vasoconstriction. PDE-5 inhibitors (e.g., sildenafil) block PDE-5 and increase cGMP levels, thereby also increasing intrahepatic and intrarenal NO bioavailability and thereby improving hemodynamics in cirrhosis [6] [7] [8] .
Despite these encouraging findings, sildenafil is not approved by the Food and Drug Administration (FDA) for use in severe hepatic impairment [12] as no pharmacokinetic or safety data in subjects with Child-Turcotte-Pugh (CTP) class C cirrhosis and renal dysfunction are available. To address this need, we treated two subjects with CTP class C cirrhosis and renal dysfunction (renal dysfunction defined as estimated glomerular filtration rate (eGFR) C15 and \60 mL/min/1.73 m 2 estimated by 6-variable modification of diet in renal disease (MDRD) equation [13] ), with a single dose of 2.5 mg sildenafil by IV bolus injection.
Methods
An investigational new drug (IND) application for sildenafil was filed with FDA, and the study was approved by the Institutional Review Board of the University of Maryland, . Both subjects denied hypersensitivity or allergy to sildenafil and its components.
After enrollment, subjects did not consume caffeinated and alcoholic beverages and avoided exercise or work activity outside their routine after enrollment. Subjects did not receive any nonselective beta-blockers, nonsteroidal anti-inflammatory drugs, diuretics, midodrine, vasopressin, or octreotide within 24 h prior to sildenafil administration and during the study. Additionally, IV fluids and albumin were stopped 2 h prior to sildenafil administration. Both subjects fasted overnight and consumed 500 mL of water before sildenafil administration. All procedures were performed in the supine position. Before sildenafil injection, mean arterial blood pressure (MAP) was checked to ascertain that it was greater than 70 mmHg. MAP along with heart rate was also measured at 15, 30, 60, 120, 180, 240, 360, and 480 min after sildenafil administration. To eliminate factors that could interfere with the absorption phase (food, slow transit time, compliance issues), each patient received single dose of 2.5 mg sildenafil by IV bolus injection. Plasma levels of sildenafil and its active metabolite N-desmethyl sildenafil levels were measured before and 15, 30, 60, 90, 120, 180, 240, 360, and 480 min after sildenafil administration. Samples were centrifuged and stored at -80°C.
Plasma Sildenafil and N-Desmethyl Sildenafil Measurements
Samples were assayed by Covance Laboratories, Inc (Madison, WI) using a validated method. Analyst Ò software (version 1.5.1) was used to capture the liquid chromatography-mass spectrophotometry/mass spectrophotometry (LC-MS/MS) data and integrate the peak areas. Watson LIMS software (Version 7.4.1) was used for data storage, management, and reporting.
Pharmacokinetic Analysis
Plasma concentrations were analyzed by noncompartmental modeling using Phoenix Ò WinNonlin Ò version 5.1 (Certara L.P. (Pharsight), St. Louis, MO).
Results
Both subjects tolerated IV sildenafil without side effects. No adverse events occurred up to 9 h after sildenafil injection. Patients did not report any adverse events when they were interviewed 48 h after sildenafil injection. Table 1 shows plasma sildenafil and N-desmethyl sildenafil concentrations before and after the administration of 2.5 mg IV sildenafil with corresponding MAP and heart rate. The pharmacokinetic parameters of sildenafil and N-desmethyl sildenafil are shown in Table 2 . The modeled maximum concentrations were 34.4 and 32.3 ng/mL, clearance 11.9 and 14.9 L/h, volumes of distribution 72.8 and 77.3 L, and half-lives 4.2 and 3.6 h. N-desmethyl sildenafil concentrations ranged from 3 to 40 % of the parent concentrations. For subject 1, the lowest MAP observed was 75 and occurred at 16 and 120 min after sildenafil injection. For subject 2, the lowest MAP was 69 mmHg and occurred at 15 min after sildenafil injection.
Discussion
We report two subjects with CTP class C cirrhosis and renal dysfunction who tolerated a single dose of 2.5 mg sildenafil by IV bolus injection without adverse events. Although prior studies reported the pharmacokinetics of sildenafil in subjects with CTP class A and B cirrhosis, no data are available on subjects with CTP class C cirrhosis [14] . In subjects with CTP class A and B cirrhosis, the mean clearance of sildenafil was reduced by 46 % and C max was increased by 47 % compared to normal controls after administration of a single 50 mg oral dose of sildenafil [14] . Additionally, the mean C max of N-desmethyl sildenafil, the active metabolite of sildenafil, was increased by 87 % compared to normal controls [14] . This increased systemic exposure in cirrhosis is likely explained by a combination of reduced hepatic clearance and reduced first-pass metabolism. We administered a single dose of 2.5 mg sildenafil by IV injection, thus eliminating the influence of first-pass metabolism on systemic exposure.
As there is no pharmacokinetic study of IV sildenafil reported in the literature conducted in subjects with CTP class A or B cirrhosis, we compared the pharmacokinetic parameters of our two subjects with CTP class C cirrhosis to those obtained from healthy volunteers. The observed C max values of 34.4 and 32.3 ng/ mL were slightly higher than the dose-corrected mean C max of 26.6 ng/mL reported in healthy volunteers [15] . Our observed clearance (CL) values of 11.9 and 14.9 L/h were 63 and 71 % lower than previous values of mean 40.8 L/h in healthy volunteers [15] . The observed volumes of distribution (Vd) values of 72.8 and 77.3 L were markedly lower than the mean volume of 234 L reported in healthy volunteers [15] . The observed half-lives of 4.2 and 3.6 h were similar to the mean half-life of 3.9 h reported in healthy volunteers [15] and may be explained by the reduced clearance and volume of distribution.
Determination of N-desmethyl sildenafil, the active metabolite of sildenafil, is important; in prior pharmacokinetic study of subjects with CTP class A and B cirrhosis, N-desmethyl sildenafil C max and area under the curve (AUC) increased by 87 and 154 % compared to healthy subjects, respectively [14] . Elimination of active metabolite of sildenafil was more impaired than sildenafil itself in subjects with CTP class A and B cirrhosis compared to healthy subjects; N-desmethyl sildenafil AUC/ BLQ below limit of quantitation a At few time points, MAP and heart rate were measured 1 or 2 min earlier or later than plasma sildenafil and N-desmethyl sildenafil concentrations sildenafil AUC in subjects with CTP class A and B cirrhosis was 71 %, whereas N-desmethyl sildenafil AUC/ sildenafil AUC in healthy subjects was only 52 % [14] . In our study, subject 1 had N-desmethyl sildenafil concentrations ranging from 3 to 40 % of the parent concentrations. Subject 2 had unmeasurable metabolite concentrations except at 180 min after sildenafil injection, likely due to the lower parent drug concentrations resulting from the low dose (2.5 mg).
To our knowledge, this is the first report of pharmacokinetics and tolerability of IV sildenafil in subjects with CTP class C cirrhosis and renal dysfunction. We conclude that sildenafil 2.5 mg injection can be safely administered in subjects with CTP class C cirrhosis and renal impairment. The observed reductions in hepatic clearance and volume, coupled with reports of reduced first-pass effect, suggest that increased systemic exposure following oral dosing in subjects with CTP class C cirrhosis would be predicted. Our findings indicate that studies of oral sildenafil in subjects with CTP class C and renal dysfunction to determine whether this benefits portal hemodynamics and renal function are safe and feasible.
